JP2021522241A5 - - Google Patents

Info

Publication number
JP2021522241A5
JP2021522241A5 JP2020559390A JP2020559390A JP2021522241A5 JP 2021522241 A5 JP2021522241 A5 JP 2021522241A5 JP 2020559390 A JP2020559390 A JP 2020559390A JP 2020559390 A JP2020559390 A JP 2020559390A JP 2021522241 A5 JP2021522241 A5 JP 2021522241A5
Authority
JP
Japan
Prior art keywords
composition according
approximately
subject
administration
control
Prior art date
Application number
JP2020559390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522241A (ja
JPWO2019229525A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000619 external-priority patent/WO2019229525A2/en
Publication of JP2021522241A publication Critical patent/JP2021522241A/ja
Publication of JPWO2019229525A5 publication Critical patent/JPWO2019229525A5/ja
Publication of JP2021522241A5 publication Critical patent/JP2021522241A5/ja
Priority to JP2024066665A priority Critical patent/JP2024096933A/ja
Withdrawn legal-status Critical Current

Links

JP2020559390A 2018-04-25 2019-04-25 抗osmrβ抗体の送達による皮膚疾患又は障害の治療 Withdrawn JP2021522241A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024066665A JP2024096933A (ja) 2018-04-25 2024-04-17 抗osmrβ抗体の送達による皮膚疾患又は障害の治療

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862662607P 2018-04-25 2018-04-25
US62/662,607 2018-04-25
US201862718324P 2018-08-13 2018-08-13
US62/718,324 2018-08-13
US201862765033P 2018-08-16 2018-08-16
US62/765,033 2018-08-16
US201862731618P 2018-09-14 2018-09-14
US62/731,618 2018-09-14
US201862757047P 2018-11-07 2018-11-07
US62/757,047 2018-11-07
US201862775350P 2018-12-04 2018-12-04
US62/775,350 2018-12-04
US201962789434P 2019-01-07 2019-01-07
US62/789,434 2019-01-07
US201962794356P 2019-01-18 2019-01-18
US62/794,356 2019-01-18
PCT/IB2019/000619 WO2019229525A2 (en) 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024066665A Division JP2024096933A (ja) 2018-04-25 2024-04-17 抗osmrβ抗体の送達による皮膚疾患又は障害の治療

Publications (3)

Publication Number Publication Date
JP2021522241A JP2021522241A (ja) 2021-08-30
JPWO2019229525A5 JPWO2019229525A5 (https=) 2022-05-06
JP2021522241A5 true JP2021522241A5 (https=) 2022-05-06

Family

ID=68234020

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559390A Withdrawn JP2021522241A (ja) 2018-04-25 2019-04-25 抗osmrβ抗体の送達による皮膚疾患又は障害の治療
JP2024066665A Pending JP2024096933A (ja) 2018-04-25 2024-04-17 抗osmrβ抗体の送達による皮膚疾患又は障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024066665A Pending JP2024096933A (ja) 2018-04-25 2024-04-17 抗osmrβ抗体の送達による皮膚疾患又は障害の治療

Country Status (12)

Country Link
US (3) US20210054085A1 (https=)
EP (1) EP3784347A2 (https=)
JP (2) JP2021522241A (https=)
KR (2) KR102849806B1 (https=)
CN (2) CN121818914A (https=)
AU (2) AU2019276779A1 (https=)
BR (1) BR112020021739A2 (https=)
CA (1) CA3096582A1 (https=)
IL (1) IL326629A (https=)
MX (2) MX2020011172A (https=)
SG (1) SG11202010034WA (https=)
WO (1) WO2019229525A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI871349B (zh) * 2020-09-01 2025-02-01 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物
US20230391878A1 (en) * 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素M受體β之抗體及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188500A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
JP6214010B2 (ja) * 2012-05-11 2017-10-18 公立大学法人和歌山県立医科大学 抗オンコスタチンm受容体ベータ抗体
SI3456743T1 (sl) * 2013-05-30 2022-01-31 Kiniksa Pharmaceuticals, Ltd. Proteini, ki vežejo antigen receptorja onkostatina M
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20170132143A (ko) * 2015-01-29 2017-12-01 옥스포드 유니버시티 이노베이션 리미티드 바이오마커
KR20170134748A (ko) * 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물

Similar Documents

Publication Publication Date Title
US20240417455A1 (en) Treatment for rheumatoid arthritis
JP6554155B2 (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
CN104010656B (zh) 使用免疫球蛋白和c1-抑制剂的联合疗法
JP2025172841A5 (https=)
JP2021523188A5 (https=)
JP2024001125A (ja) Il-17アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2021522241A5 (https=)
JP2020535149A5 (https=)
JP2022121658A (ja) アミロイドーシスを処置するための組成物
Robak et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura
CN107849128A (zh) 瘙痒治疗
JPWO2019229525A5 (https=)
CA3176673A1 (en) Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
Nowak et al. Reviewing the current treatment approaches for bullous pemphigoid–analysis of literature
CA2884124C (en) Treatment for rheumatoid arthritis
JPWO2021161270A5 (https=)
JPWO2021191220A5 (https=)
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
NZ773889B2 (en) Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
JPWO2020188466A5 (https=)
NZ773889A (en) Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
JPWO2021255189A5 (https=)
JPWO2024026395A5 (https=)
HK40064997A (en) Treatment for rheumatoid arthritis with anti-gm-csf antibody